PRINCETON, N.J. - Bristol Myers Squibb (NYSE:BMY) is on the verge of finalizing its acquisition of RayzeBio, Inc. (Nasdaq:RYZB), as the tender offer to purchase all outstanding shares of RayzeBio for $62.50 per share in cash, totaling approximately $4.1 billion, successfully concluded on February 22, 2024. The transaction is anticipated to close on February 26, 2024, following the acceptance of approximately 86% of RayzeBio's issued and outstanding common stock, which were validly tendered and not withdrawn by the expiration time.
The acquisition is a significant move by Bristol Myers Squibb, a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. The tender offer's successful completion indicates strong support from RayzeBio's shareholders for the transaction.
The parties involved expect that the final steps of the acquisition process will proceed without issue, leading to the consolidation of RayzeBio into Bristol Myers Squibb's operations. This strategic move aims to enhance Bristol Myers Squibb's portfolio and capabilities in the biopharmaceutical sector.
RayzeBio stockholders who may have inquiries regarding the offer can reach out to Georgeson LLC, the information agent for the offer. The tender offer materials, including the offer to purchase and a solicitation/recommendation statement, have been made available to investors and security holders, who are advised to read them carefully for detailed information about the offer.
This acquisition is subject to standard closing conditions and regulatory approvals. Bristol Myers Squibb has not provided any guidance on the expected benefits or synergies from the acquisition at this time. Investors are cautioned that forward-looking statements regarding the acquisition involve risks and uncertainties that could cause actual results to differ materially from current expectations.
This news article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.